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Introduction
Tocilizumab (TCZ) is an anti-interleukin-6 receptor
antibody. It has been accepted as a biological treatment
in some subtypes of Juvenile Idiopathic Arthritis. Off-
label it has been used (compassionate use) in some
refractory pediatric autoimmune disorders. Despite
being an effective treatment in most cases, this drug
isn’t exempt of adverse events.
Objectives
To describe a patient affected by an overlap autoim-
mune syndrome who presents an inflammatory myopa-
thy as a rare complication during TCZ treatment.
Methods
A 6-year-old boy affected by an overlap autoimmune
syndrome characterized by facial skin lesions chilblain
lupus like (histopathologically compatible with leukocy-
toclastic vasculitis), recurrent skin urticarial episodes
and a severe lung disease (in the anatomopathological
study is a linfoid intersticial neumonitis). He presents
antinuclear antibodies positivity (maximum title
reported 1/640), an undetermined antiDNA antibodies
title (values around 31 UI/ml), no complement con-
sumption of C3 neither C4, positives antiB2-glycopro-
tein and anticardiolipin IgG antibodies with persisting
elevation of acute phase reactants highlighting an ESR
permanently around 100 mm/h and thrombocytosis
around 500x10^9 platelets. An extended auto-antibodies
study was repeatedly performed without finding other
auto-antibodies positivity. Several therapeutic strategies
with different agents were previously tested (corticoids,
azathioprine, hydroxychloroquine, anakinra, mycopheno-
late, gammaglobulin, tacrolimus). All of these therapies
were discontinued because of inefficacy or lack of effi-
cacy, and resolution of symptoms wasn’t achieved.
Results
After a multidisciplinary evaluation TCZ treatment was
initiated. After the first dose he presented improvement
of general condition, of skin lesions and of the exertional
dyspnea and a dramatical decrease in the acute phase
reactants values. Two months later he referred subacute
inflammatory pain in both lower limbs, predominantly
proximal and symmetrical. The blood test revealed eleva-
tion of liver and muscular enzymes: alanine aminotrans-
ferase 91 UI/L, aspartate aminotransferase 59 UI/L,
creatine kinase 1008 UI/L, aldolase 34.3 UI/L, lactate
dehydrogenase 695 UI/L. A bilateral lower limb MRI was
performed confirming enhanced STIR signal and edema
affecting multiple muscles: right transverse abdominal
muscle, bilateral gluteal muscles (maximus, medius and
minimus), almost all muscle groups in both thighs
respecting the intermedius and medialis vastus, the short
and long adductors, and partially the magnus adductor.
Inflammatory lesions of practically all muscle groups
respecting the posterior tibial and soleus muscles in both
legs were also observed. To sum up, a bilateral inflamma-
tory myopathy was detected from abdomen to ankles.
Intravenous gammaglobulin 1mg/kg/14 days treatment
was introduced and TCZ discontinued achieving a fast
improving in pain, function and normalizing blood para-
meters related with muscle inflammation. Two months
later the myositis episode was on clinical and biological
remission but the autoimmune disease continues.
Conclusion
We report a case of inflammatory myopathy attributed
as a rare complication after Tocilizumab treatment. To
our knowledge, this adverse event of Tocilizumab treat-
ment wasn’t previously described.
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